Onpattro (Patisiran) for Amyloidosis

Overview
Onpattro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve damage resulting from hereditary transthyretin-mediated (hATTR) amyloidosis. Onpattro is also referred to by its drug name, patisiran.

Onpattro is a member of a class of drugs called small interfering ribonucleic acids (siRNA). Onpattro is believed to work by interfering with the creation of amyloid proteins in cells.

How do I take it?
Prescribing information states that Onpattro is given as an intravenous infusion (slow injection into a vein) by a health care professional. Onpattro is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Side effects
The FDA-approved label for Onpattro lists common side effects as upper respiratory tract infections and infusion reactions that include back, neck, or other muscle pain; flushing; nausea; abdominal pain; difficulty breathing or cough; chest discomfort or pain; headache; rash; chills; dizziness; fatigue; increased heart rate or palpitations; hypotension (low blood pressure) or hypertension (high blood pressure); and facial edema (swelling).

A serious side effect listed for Onpattro is vitamin A deficiency.

For more details about this treatment, visit:
Onpattro — Alnylam
Onpattro — Alnylam Assist